RepliCel Life Sciences, Inc.
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.replicel.com
Clinical Trials
3
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Long-Term Follow-up of the Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis
Withdrawn
- Conditions
- TendinosisTendinopathy
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2016-04-07
- Lead Sponsor
- RepliCel Life Sciences, Inc.
- Registration Number
- NCT02655042
- Locations
- 🇨🇦
Alan McGavin Sports Medicine Centre, Vancouver, British Columbia, Canada
Study of Intradermal Injections of RCS-01 in Male and Female Subjects
Phase 1
Completed
- Conditions
- Intrinsic Aging of SkinSkin WrinklingSolar Degeneration of Skin
- Interventions
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2017-10-11
- Lead Sponsor
- RepliCel Life Sciences, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT02391935
- Locations
- 🇩🇪
IUF Leibniz-Institut für umweltmedizinische Forschung gGmbH, Düsseldorf, Germany
Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis
- First Posted Date
- 2015-01-01
- Last Posted Date
- 2017-09-28
- Lead Sponsor
- RepliCel Life Sciences, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT02330146
- Locations
- 🇨🇦
Allan McGavin Sports Medicine Centre, Vancouver, British Columbia, Canada
News
No news found